Heads up: this issue is from October 30, 2025. Because it covers time-sensitive coding and regulatory topics, some details may have changed since. See the latest issues for current guidance.
Recently, the Trump administration unveiled a new drug pricing initiative, widely referred to as “TrumpRx.” TrumpRx (reportedly operational in January 2026) is defined by two key aspects: (1) a government-run portal aimed at directing patients to a website to purchase drugs (without going through their insurance) at discounted rates set by the government; and (2) tactics designed to force concessions from drug manufacturers.
While the headlines surrounding TrumpRx amplify its hype, the reality is more complex (maybe)—and the expected ramifications will affect pharmacies, plan sponsors, and Pharmacy Benefit Managers (PBMs). This article outlines the administration’s actions towards drug pricing thus far and what TrumpRx could mean for the pharmaceutical marketplace.
The Portal
As noted, TrumpRx is characterized by: a government-run portal that may send patients to manufacturers’ DTC websites to purchase medications without using their insurance, and trade and pricing tactics that might force drug manufacturers to grant further concessions. TrumpRx, as advertised, is a regression to self-pay. For pharmacies, this means direct competition with drug manufacturers for some prescriptions.
For plan sponsors, i.e., employers, the portal has issues. Members who bypass their insurance to purchase through TrumpRx will save money individually, but the plan itself loses oversight of drug utilization. This evaporates data that employers need for care management, adherence monitoring, and formulary strategy.
The second key aspect of TrumpRx involves tariff threats on imported pharmaceuticals. This further pressures manufacturers to adjust their pricing, which, if successful, would inevitably create new benchmarks that employers will expect in commercial negotiations. If negotiations fail, tariffs could become even more likely. This encourages manufacturers to build more facilities in the U.S. For pharmacies, this creates uncertainty, as acquisition costs may fluctuate depending on the outcome of tariff negotiations.
The administration’s strategic use of these tactics appears to be successful. Pfizer has already made a deal, and we are seeing a few other manufacturers selling a single product directly to consumers to test the waters.
Drug Pricing Effects
The Inflation Reduction Act (IRA), passed in 2022 during the Biden administration, requires drug manufacturers of certain drugs to pay rebates to Medicare if prices rise faster than inflation. It also grants the federal government the authority to negotiate prices for a select number of high-spend Medicare Part D and Part B drugs, setting a maximum fair price (MFP). Part D already has negotiated prices; the Part B process will start next year.
The provisions of the IRA only directly affect Medicare Fee-for-Service. The impact may be felt indirectly across commercial payers (or not). Manufacturers may cost-shift in commercial rates while absorbing mandated Medicare cuts. Overall, the IRA can put pressure on branded drug pricing, potentially influencing reimbursement strategies across all payers.
As we have reported previously, in May 2025, the Trump administration revived an idea first floated in 2020 by issuing an Executive Order ("EO") entitled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” This EO outlined the administration’s “most favored nation” (MFN) drug pricing strategy, which aims to align U.S. prescription drug prices with the lowest prices charged for the same medications in developed countries (whoever that may be). Since the EO was issued, the Trump administration has pursued or announced more measures on drug pricing. This includes a 100% tariff on brand-name and patented pharmaceutical products, unless a company commits to building manufacturing plants in the U.S., though the tariff appears unenforced.
On September 30, the administration announced the details of its first negotiated deal with Pfizer, which grants every single State Medicaid program access to MFN drug prices on Pfizer products and ensures MFN prices for all new medicines introduced by Pfizer. Additionally, Pfizer will reportedly be required to repatriate increased revenue from existing products due to U.S. trade policies and offer drugs at substantial discounts when selling directly to U.S. patients.
While broad MFN implementation may have some substantial problems (e.g., conflicts with the IRA and other federal pricing frameworks such as the 340B Drug Discount Program, the Medicare Inflation Rebates, and/or the Medicaid Drug Rebate Program), its role as a negotiation tool remains influential. If Medicare (Pfizer's deal says nothing about Medicare) does adopt lower MFN-style prices, the commercial market will struggle to justify significantly higher allowables.
Pharmacy and Channel Effects
The real impact of TrumpRx on pharmacies is not just about lowering revenues. When manufacturers sell directly to patients through TrumpRx, those prescriptions theoretically can bypass the pharmacy altogether. In turn, pharmacies, particularly what's left of independent pharmacies, could see patients drift to manufacturer portals if they cannot match cash pricing or if manufacturers restrict sales to direct fulfillment through TrumpRx. What happens to pharmacies and distribution channels?
Specialty pharmacies also face heightened risk as high-priced, high-demand biologics are likely candidates for TrumpRx discounting. If such products shift to DTC channels, specialty pharmacies could lose a significant share of patient volume.
Employer Effects
The existence of government-advertised discounts will prompt employees to question why their employer-sponsored plan cannot offer similar pricing, particularly as employee costs rise. TrumpRx transparency will put pressure on human resource leaders and benefits committees to renegotiate PBM contracts.
Moreover, direct purchase arrangements, carve-outs, and alternative funding models (no!) may gain popularity as employers seek ways to replicate the patient-facing savings offered by TrumpRx. However, these arrangements must be carefully designed to avoid compliance pitfalls, particularly under the Employee Retirement Income Security Act (The ERISA Shield) and state insurance laws.
PBM Effects (Boo hoo)
The political and legal environment surrounding PBMs is already hostile (duh). This is further exemplified by the Federal Trade Commission’s lawsuits challenging their rebate practices and those of their affiliated group purchasing organizations (GPOs). Additionally, stakeholders are increasingly skeptical of opaque rebate contracting. With TrumpRx showcasing an alternative—discounts that patients can see and touch—the traditional PBM value proposition appears to grow weaker by the day. CIGNA, for example, just announced its departure from traditional PBM rebates.
PBM-affiliated rebate aggregators have also drawn regulatory and provider scrutiny. These entities pool purchasing power to negotiate rebates on behalf of multiple PBMs, creating another layer of opacity. PBMs or provider organizations sometimes own these. The FTC has already flagged that these arrangements limit competition and inflate costs. TrumpRx intensifies scrutiny of PBM-affiliated rebate aggregators. For example, if discounts flow directly to patients through a government portal, the rationale for complex rebate schemes becomes less compelling.
Questions
Many questions remain before launch, whenever that may be. Some that occur to me:
- Will patients really want to pay cash if the price is higher than purchasing an insurance policy through the ACA or going on Medicaid?
- Will TrumpRx pricing be lower than the patient's out-of-pocket? Will patients cherry-pick TrumpRx during their deductible period and go to insurance when it's over?
- What if very few manufacturers discount their prices, and there is not enough choice for patients to even be aware of TrumpRx?
- Will Patient Assistance programs help qualified patients with highly discounted prices? Foundations?
Food for thought--we shall see!
